Business Context and Reporting Period
Company: Repligen Corporation (RGEN)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2011
Business Overview: Repligen is an integrated biopharmaceutical company with two primary business segments: (1) a bioprocessing business manufacturing Protein A resins and Opus pre-packed chromatography columns for the production of biopharmaceuticals, and (2) a therapeutic development pipeline focused on neurology and gastroenterology (e.g., pancreatitis, Friedreich's ataxia, spinal muscular atrophy). The company also generates royalty revenue from Bristol-Myers Squibb regarding the drug Orencia.
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 | Fiscal 2009 |
|---|---|---|---|
| Total Revenue | $27.29 million | $20.97 million | $29.36 million |
| Net Income (Loss) | $(0.04) million | $(4.06) million | $5.75 million |
| Operating Income (Loss) | $(0.37) million | $(5.77) million | $3.88 million |
| Research & Development Expenses | $12.53 million | $14.16 million | $12.77 million |
| Cash and Marketable Securities | $61.50 million | $59.15 million | $63.96 million |
| Working Capital | $51.22 million | $55.02 million | $50.24 million |
| Long-term Obligations | $0.58 million | $0.64 million | $0.08 million |
Note: Revenue is comprised of Product Revenue ($14.96M) and Royalty/Other Revenue ($12.33M). The company reported a net loss of $43,509 for the fiscal year.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30% to $27.29 million compared to $20.97 million in fiscal 2010. This was driven primarily by a 45% increase in bioprocessing product sales ($14.96M vs. $10.31M) due to higher volume from key customers.
- Royalty Revenue: Royalty revenue from Bristol-Myers Squibb (Orencia) increased 14% to approximately $10.25 million. Royalty revenue from ChiRhoClin ceased as obligations were fulfilled in late 2009.
- Profitability: The company narrowed its net loss significantly from $4.06 million in 2010 to $0.04 million in 2011, moving closer to breakeven.
- R&D Expenses: Research and development expenses decreased 12% to $12.53 million, primarily due to the completion of the Phase 3 re-analysis for the secretin program (RG1068) and the conclusion of the Phase 2b trial for the uridine program (RG2417).
- Investing Activities: The company utilized $1.5 million in cash for investing activities, including a $300,000 milestone payment for the BioFlash acquisition and capital expenditures.
Guidance, Outlook, and Risks
- Product Launches: Management plans to file a New Drug Application (NDA) with the FDA for RG1068 (secretin for MRI imaging of the pancreas) in the second quarter of fiscal 2012. Commercial infrastructure is being built for a potential U.S. launch.
- Clinical Trials: The company intends to initiate Phase 1 studies for RG2833 (Friedreich's ataxia) and RG3039 (spinal muscular atrophy) in fiscal 2012, pending regulatory approvals.
- Bioprocessing Outlook: Bioprocessing sales are expected to increase moderately in fiscal 2012, though subject to quarterly fluctuations based on large-scale production orders.
- Liquidity: With $61.5 million in cash and marketable securities, management believes current balances are adequate to meet cash needs for at least the next 24 months.
- Key Risks:
- Customer Concentration: The company relies heavily on a limited number of customers. Bristol-Myers Squibb royalties represented 38% of total revenue, and the largest bioprocessing customer accounted for 42%.
- Regulatory Approval: Future revenue is contingent on FDA approval of RG1068 and other pipeline candidates. The NDA for RG1068 is based on a single re-read of Phase 3 data, which the FDA may not deem sufficient.
- Patent Expiration: Key U.S. patents for recombinant Protein A expired in September 2009, potentially increasing competition.
Investor Verification Checklist
- Royalty Dependency: Verify the stability of royalty revenue from Bristol-Myers Squibb, which constitutes a significant portion of total revenue and is dependent on Orencia sales outside Repligen's control.
- RG1068 NDA Status: Monitor the FDA's review of the New Drug Application for RG1068, expected in Q2 fiscal 2012, as this is the primary near-term catalyst for therapeutic revenue.
- Customer Concentration: Assess the risk associated with the top bioprocessing customer (42% of revenue) and the potential impact of order deferrals or loss of this client.
- Cash Burn Rate: Confirm that the $61.5 million cash balance remains sufficient to fund the planned Phase 1 trials and commercialization efforts without requiring dilutive equity financing.
- Patent Landscape: Review the competitive landscape for Protein A products following the expiration of the primary U.S. patent in 2009.